What is the detailed management of thyroid eye disease (Graves' ophthalmopathy), including the role of orbital radiotherapy?

Thyroid Eye Disease Management

For thyroid eye disease (TED), management follows a stepwise approach based on disease severity and activity, with orbital radiotherapy (typically 20 Gy in 10 fractions) reserved for moderate-to-severe active disease, particularly when combined with corticosteroids or as second-line therapy for steroid-resistant cases. 1

Initial Assessment and Risk Factor Modification

Essential Diagnostic Workup

• Exophthalmometry to quantify proptosis and track progression
• Complete motility examination with forced duction testing to identify restrictive myopathy
• Optic nerve surveillance: visual acuity, color vision, visual fields, pupillary exam, fundus examination for disc edema/atrophy
• OCT and automated visual fields to screen for compressive optic neuropathy
• Orbital CT or MRI showing tendon-sparing extraocular muscle enlargement (inferior rectus most common, then medial rectus), orbital apex crowding, and proptosis 1, 2
• Clinical Activity Score (CAS) to determine disease activity 3, 4

Universal Interventions (All Patients)

• Smoking cessation (mandatory counseling - smoking dramatically worsens disease) 2
• Ocular lubricants for exposure keratopathy from lid retraction/proptosis
• Punctal plugs when needed 1
• Thyroid function optimization (euthyroid state essential) 1

Treatment Algorithm by Disease Severity

Mild TED (No diplopia in primary/reading position)

• Watchful waiting with close monitoring 1, 2
• Selenium supplementation (100 mcg twice daily for 6 months) in selenium-deficient patients reduces inflammatory symptoms and prevents progression 1, 5
• Continue local measures and risk factor control

Moderate-to-Severe Active TED

First-Line: High-Dose Intravenous Corticosteroids

• Methylprednisolone IV: 500 mg weekly × 6 weeks, then 250 mg weekly × 6 weeks (cumulative 4.5-5 g) 3, 5
• More severe cases may require up to 8 g cumulative dose 5
• Monitor for vision-threatening complications: compressive optic neuropathy, severe exposure keratopathy, elevated IOP 2

Second-Line Options (Steroid-Resistant or Steroid-Dependent Disease)

Orbital Radiotherapy:

• Dose: 20 Gy in 10 fractions (standard protocol) 1, 6, 7
  • Alternative: 10 Gy in 5-10 fractions shows comparable efficacy with lower toxicity 4
• Optimal timing: Active phase of disease (high CAS), ideally administered during steroid therapy 3, 4, 7
• Best candidates 6, 7:
  • Moderate-to-severe active TED with significant motility deficits
  • Compressive optic neuropathy (may obviate urgent surgical decompression)
  • Progressive strabismus
  • Steroid-resistant disease
  • Patients requiring steroid taper facilitation

Evidence for Radiotherapy Efficacy:

• Significant CAS reduction sustained at 12 months (Cohen's d = 10.88) 3
• Improves diplopia and soft tissue signs 6
• Prevents/treats compressive optic neuropathy 6
• Minimal adverse events: only G1-G2 acute eye disorders, no xerophthalmia or cataracts in recent series 4
• Disease reactivation rare (only 2/62 patients in one series) 3

Alternative Biologics:

• Teprotumumab (IGF-1R inhibitor): Reduces proptosis, CAS, diplopia, and need for strabismus surgery 1, 8
  • Contraindications: Pregnancy (absolute), inflammatory bowel disease (relative), pre-existing hearing loss (caution)
  • Side effects: Hyperglycemia, muscle spasms, nausea, alopecia, diarrhea, tinnitus/hearing impairment (30%), dysgeusia, weight loss 1, 8
  • High cost and relapse rate limit widespread use 8
• Tocilizumab (IL-6 receptor blocker): Effective for steroid-resistant cases 8
• Rituximab, Fingolimod: Used in Europe 1

Vision-Threatening TED (Compressive Optic Neuropathy)

Immediate interventions:

1. High-dose pulse IV methylprednisolone 1
2. Orbital radiotherapy (can postpone urgent decompression until inactive phase) 1, 6, 7
3. Urgent orbital decompression if medical management fails 1

Critical caveat: Refer immediately to orbital specialist for vision-threatening disease, moderate-to-severe exophthalmos, or significant orbital pain 2

Surgical Timing and Sequence

The surgical sequence must follow strict order 1:

1. Wait for disease stability: Angle of strabismus stable for 4-6 months minimum, no active inflammation 1
2. Orbital decompression first (if needed) - significantly alters alignment 1
3. Strabismus surgery second - after decompression, as displacement of muscles into newly available space changes motility 1
4. Eyelid surgery last - delayed until after strabismus repair 1

Important pitfall: Rectus muscle recession can worsen proptosis; consider decompression consultation even without optic neuropathy if concurrent significant proptosis and strabismus exist 1

Nonsurgical Diplopia Management

• Fresnel or ground-in prisms: Temporary relief during active phase or for small residual deviations post-surgery 1, 2
• Botulinum toxin chemodenervation: During active phase may provide temporary relief and possibly reduce final misalignment 1, 2

Monitoring During Treatment

• Serial exophthalmometry
• CAS assessment at each visit
• Visual function testing (acuity, color, fields, pupils)
• Motility measurements
• Imaging (CT/MRI) to assess muscle size and orbital apex crowding 1, 2
• MRI sequences (T2 FSE, T1Gad, STIR) can determine disease quiescence when clinical assessment unclear 1

Key Clinical Pitfalls

1. Don't use radiotherapy in mild or inactive disease - no benefit over natural history 7
2. Radiotherapy requires demonstration of steroid responsiveness - confirms immunomodulatory therapeutic potential 7
3. Preserve inferomedial orbital strut during decompression - reduces new-onset strabismus risk 1
4. Screen for myasthenia gravis - increased incidence in TED patients 2, 1
5. Avoid radioactive iodine for hyperthyroidism during active TED - increases risk of progression 2, 9